0.00
-0.0429(-99.77%)
Currency In USD
Address
1717 Main Street
Dallas, TX 75201
United States of America
Phone
254 244 5739
Website
Sector
Healthcare
Industry
Biotechnology
Employees
57
First IPO Date
November 11, 2021
| Name | Title | Pay | Year Born |
| Ms. Mei Mei Hu J.D. | Co-Founder, President, Chief Executive Officer & Director | 345,143 | 1983 |
| Mr. Louis Garfield Reese IV | Co-Founder & Executive Chairman of the Board | 275,575 | 1982 |
| Ms. Sumita Ray J.D. | Chief Legal, Compliance & Administrative Officer and Corporate Secretary | 465,557 | 1974 |
| Dr. Jean-Cosme Dodart Ph.D. | Chief Scientific Officer | 0 | N/A |
| Mr. Mark Joinnides MSE | Chief of Staff | 0 | N/A |
| Mr. Jason Pesile CPA, M.B.A. | Chief Accounting Officer | 0 | 1973 |
| Dr. Manal Morsy M.B.A., M.D., PH.D. | Chief Regulatory Officer | 0 | N/A |
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.